Nucleix For Profit
Nucleix is an organization that specializes in the development, manufacturing, and marketing of non-invasive molecular cancer diagnostic tests. Their tests are designed to detect cancer at an early stage, when treatment is most effective. Nucleix offers tests such as Bladder EpiCheck, a urine test for monitoring bladder cancer, and Lung EpiCheck, a blood test for early detection of lung cancer. The organization was founded in 2008 and is headquartered in Rehovot, Israel. They are committed to delivering highly accurate and sensitive results, and are working with leading medical centers and laboratories worldwide.
Investors
Funding Status:
Seed
Headquarters:
Rehovot, HaMerkaz, Israel
Founded Date:
2008
Employee Number:
69
Estimated Revenue:
$12.9Mper year
Industry:
Deep Diagnostics
Technology:
Biomarker panels
Investor Type:
N/A
Number Of Exists:
11-50
Investment Stage:
N/A